HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and maintained an $18 price target for the company's stock.

December 05, 2023 | 11:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reaffirmed a Buy rating on Travere Therapeutics with a steady price target of $18, indicating a positive outlook for the stock.
The reiteration of a Buy rating and maintenance of the price target by a reputable analyst can lead to increased investor confidence and a potential short-term uplift in the stock price. The specific mention of the company and the reaffirmation of the price target suggest a strong conviction in the company's prospects, which could positively influence the stock's performance in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100